<DOC>
	<DOCNO>NCT00583232</DOCNO>
	<brief_summary>The metabolic response Crohn 's disease , include increase proteolysis lipolysis change energy expenditure , play significant role result malnutrition patient suffer . Tumor necrosis factor-alpha ( TNF-alpha ) , pro-inflammatory cytokine , find elevate child ulcerative colitis . TNF-alpha incriminate mechanism weight loss many different chronic disease , cause net protein lipid catabolism . Anti-TNF-alpha antibody ( infliximab ) proven effective therapy ulcerative colitis . The purpose study compare change protein lipid metabolism , well rest energy expenditure , therapy anti-TNF-alpha antibody ( infliximab ) corticosteroids child recurrent Crohn 's disease . Performing study well define change nutrition status observe child follow remission active Crohn 's disease , potentially lead change medical nutritional management child .</brief_summary>
	<brief_title>Protein Energy Metabolism Pediatric Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female child age six eighteen year age recurrence active Crohn 's disease , determine primary pediatric gastroenterologist require either : 1 . Corticosteroid therapy ( ( 12 mg/kg/d maximum 60 mg/day ) taper , 2 . Infliximab therapy ( 5 mg/kg 0 , 2 , 6 week , follow q 8 week therapy ) Crohn 's disease least 3 month since diagnosis , gastritis , duodenitis , ileitis , ileocolitis , colitis , confirm endoscopy biopsy PCDAI score &gt; 20 If receive concomitant medication , must stable regimen follow : 1 . Subjects aminosalicylates and/or immunomodulators stable dose least 2 week prior enrollment . 2 . Subjects must oral , rectal , parenteral corticosteroid least 2 week prior enrollment . Screening laboratory test meet follow criterion ( obtain within 4 week enrollment ) : 1 . Hemoglobin &gt; 8.0 g/dL 2 . White blood cell count &gt; 3.5 x 109/L 3 . Neutrophils &gt; 1.5 x 109/L 4 . Platelets &gt; 100 x 109/L 5 . Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase level within 3 time upper limit normal . For patient receive infliximab , PPD skin test skin induration &lt; 5 mm . Signed write consent parent/legal guardian assent child obtain prior enrollment . Local manifestation Crohn 's disease , include fistula ( ) , strictures , abscess , complication surgery may indicate . Surgery bowel diversion placement stoma within 3 month prior screen . Positive stool examination enteric pathogen include Salmonella Shigella specie , Clostridium difficile , Giardia lamblia . Female subject pregnant , nursing , plan pregnancy . Concomitant diagnosis history congestive heart failure . Treatment parenteral nutrition within 4 week enrollment . Serious infection 3 month prior enrollment . History prior current active latent tuberculosis . Immune deficiency syndrome , include document human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) . History systemic lupus erythematosus . A transplanted organ . Known malignancy history malignancy within 5 year enrollment . History demyelinate disease . History substance abuse . Poor tolerability venipuncture lack venous access study period . A live virus vaccination within 3 month enrollment . Prior history infliximab infusion , therapeutic agent target reduce tumor necrosis factora ( TNFa ) . Hypersensitivity murine proteins component infliximab patient receive infliximab . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>protein metabolism</keyword>
	<keyword>energy metabolism</keyword>
</DOC>